» Articles » PMID: 37353886

Diagnosis of Menke-Hennekam Syndrome by Prenatal Whole Exome Sequencing and Review of Prenatal Signs

Abstract

Introduction: CREBBP truncating mutations and deletions are responsible for the well-known Rubinstein-Taybi syndrome. Recently, a new, distinct CREBBP-linked syndrome has been described: missense mutations located at the 3' end of exon 30 and the 5' portion of exon 31 induce Menke-Hennekam syndrome. Patients with this syndrome present a recognizable facial dysmorphism, intellectual disability of variable severity, microcephaly, short stature, autism, epilepsy, visual and hearing impairments, feeding problems, upper airway infections, scoliosis, and/or kyphosis. To date, all diagnoses were made postnatally.

Method And Case Report: Trio-whole exome sequencing (WES) was performed in a fetus showing increased nuchal translucency persistence and aorta abnormalities at 28 weeks of gestation (WG).

Results: WES revealed a CREBBP de novo missense mutation (c.5602C>T; p.Arg1868Trp) in exon 31, previously reported as the cause of Menke-Hennekam syndrome. Termination of pregnancy was performed at 32 WG. We further reviewed the prenatal signs of Menke-Hennekam syndrome already reported. Among the 35 patients reported and diagnosed postnatally up to this day, 15 presented recognizable prenatal signs, the most frequent being intra-uterine growth retardation, brain, and cardiovascular anomalies.

Conclusion: Menke-Hennekam is a rare syndrome with unspecific, heterogeneous, and inconstant prenatal symptoms occurring most frequently with the c.5602C>T, p.(Arg1868Trp) mutation. Therefore, the prenatal diagnosis of Menke-Hennekam syndrome is only possible by molecular investigation. Moreover, this case report and review reinforce the importance of performing prenatal WES when unspecific signs are present on imaging.

Citing Articles

Diagnosis of Menke-Hennekam syndrome by prenatal whole exome sequencing and review of prenatal signs.

Cogan G, Bourgon N, Borghese R, Julien E, Jaquette A, Stos B Mol Genet Genomic Med. 2023; 11(9):e2219.

PMID: 37353886 PMC: 10496051. DOI: 10.1002/mgg3.2219.

References
1.
Dutto I, Scalera C, Prosperi E . CREBBP and p300 lysine acetyl transferases in the DNA damage response. Cell Mol Life Sci. 2017; 75(8):1325-1338. PMC: 11105205. DOI: 10.1007/s00018-017-2717-4. View

2.
De Guzman R, Liu H, Dyson H, Wright P . Solution structure of the TAZ2 (CH3) domain of the transcriptional adaptor protein CBP. J Mol Biol. 2000; 303(2):243-53. DOI: 10.1006/jmbi.2000.4141. View

3.
Banka S, Sayer R, Breen C, Barton S, Pavaine J, Sheppard S . Genotype-phenotype specificity in Menke-Hennekam syndrome caused by missense variants in exon 30 or 31 of CREBBP. Am J Med Genet A. 2019; 179(6):1058-1062. DOI: 10.1002/ajmg.a.61131. View

4.
Milani D, Manzoni F, Pezzani L, Ajmone P, Gervasini C, Menni F . Rubinstein-Taybi syndrome: clinical features, genetic basis, diagnosis, and management. Ital J Pediatr. 2015; 41:4. PMC: 4308897. DOI: 10.1186/s13052-015-0110-1. View

5.
Nishi E, Takenouchi T, Miya F, Uehara T, Yanagi K, Hasegawa Y . The novel and recurrent variants in exon 31 of CREBBP in Japanese patients with Menke-Hennekam syndrome. Am J Med Genet A. 2021; 188(2):446-453. DOI: 10.1002/ajmg.a.62533. View